In a phase 1 study, gilteritinib in combination with a standard 3 + 7 regimen (idarubicin and cytarabine (IDA/AraC)) showed high response rates (89%) with acceptable toxicity in patients with FLT3-mutated AML [120]. Here, FLT3 is linked to acute myeloid leukemia.